The Medical Management Department of the National Medical Security Bureau of China said, Pfizer PfizerPAXLOVID, which treats crown disease, has not been included in the latest list of national basic medical insurance for basic medical insurance. The negotiation of high prices of drugs has not been successful.
According to Global Network, the National Medical Insurance Drug Catalog Work Sunday (January 8) officially ended.The person in charge of the Medical Management Department of the National Medical Security Bureau introduced the relevant situation of the negotiations of the Crown Diseases to participate in the negotiations of the medical insurance drug catalog.
The person in charge said that this year, there are three types of crowning drugs in Azf's fixed tablet, Neymar's tablets/Litonovir tablets (hereinafter referred to as "Paxlovid") and clearing lung detox particles.He participated in the negotiations through procedures such as independent application, formal review, and expert review.Among them, the negotiations of Azf's fixed slices and lung detoxification particles were successfully negotiated, and Paxlovid failed to succeed due to high quotation of Pfizer.
The person in charge said that although Paxlovid failed to include the medical insurance directory through negotiations, according to the recently issued by the State Medical Insurance Administration and the relevant departments, the treatment cost of the treatment of new type of coronary infection was optimized after the implementation of the "Class B tube".Notice of medical security related policies (hereinafter referred to as notification) requirements, all therapeutic drugs in the new coronary virus infection diagnosis and treatment plan (Trial Tenth Edition), including PAXLOVID, Azf fixed chip, Monoraville capsule, dispersion and chillingWet particles, etc., medical insurance will be paid temporarily until March 31, 2023.During this period, insured patients with coronal virus infection can enjoy medical insurance reimbursement policies with these drugs.
In addition, after the negotiations were included in the national medical insurance drug catalog after this negotiation, more than 600 drugs such as the treatment of fever and cough have been treated in the national medical insurance drug directory.
It is reported that Paxlovid was approved in China in February 2022, and was used in the Shanghai epidemic in March 2022.
With the rapid rise in the number of infections from all over China, many public and private hospitals revealed that Paxlovid is currently out of stock or only uses patients with symptomatic patients.Many symptoms of mild symptoms turn to other channels to buy medicine.It was reported earlier that the price of a box of Paxlovid's black market has been fired to tens of thousands of yuan (RMB, about S $ 1950).
